Amgen presents NESP, SD/01 and KGF data

Data from a Phase II open label dose escalation and pharmacokinetics trial showed that AMGN's novel erythropoiesis stimulating protein (NESP) had a 50 hour

Read the full 247 word article

How to gain access

Continue reading with a
two-week free trial.